



Paclitaxel 80, Breast Cancer, adjuvant

Protocol-ID: 581 V1.2 (Short), PACL80, Breast Ca, adj.

Indication(s)

- Breast Cancer; ICD-10 C50.-

Protocol classification

- Classification: alternative
- Intensity: Standard dose
- Therapy phase:
- Therapy intention: curative

Cycles

Cycle length 7 days, recommended cycles: 12

Protocol sequences

- [EC \(EPIR90/CYCL600\), Breast Ca, adj. \(PID579\) -|- PACL80, Breast Ca, adj. \(PID581\)](#)
- [EC \(EPIR90/CYCL600\), Breast Ca, adj., dd \(PID2702\) -|- PACL80, adj. \(PID581\)](#)
- [SWOG S0221: AC \(DOXO60/CYCL600\), Breast Ca, adj., dd, var. 1 \(PID478\) -|- PACL80, adj. \(PID581\)](#)
- [AC \(DOXO60/CYCL600\), Breast Ca, adj. \(PID599\) -|- PACL80, adj. \(PID581\)](#)

Risks

- Emetogenicity (MASCC/ESMO): low (10-30%)
- Neutropenia: low (<10%) °3-4: 2%
- Febrile Neutropenia: low (<10%) °3-4: 1%
- Infections: CTC AE °3-4: 3%
- Fatigue: CTC AE °3-4: 3%
- Neuropathy: CTC AE °2-4: 27%
- Myalgias: CTC AE °3-4: 2%

Therapy

Hydration: Balanced Crystalloid Solution

HYD

Access: peripheral venous

Hydration before, during, or after antitumor therapy

Day	Substance	Dosage	Solution	Appl.	Inf. time	Procedure
1	Balanced Crystalloid Solution	500 ml		i.v.	30 min	30 min before Paclitaxel (d1)

Allergy prophylaxis: Paclitaxel Allergy Prophylaxis

AP

Access: peripheral venous

Dexamethasone, dimetinden maleate, cimetidine

Day	Substance	Dosage	Solution	Appl.	Inf. time	Procedure
1	Dexamethasone	20 mg	NaCl 0.9% 50 ml	i.v.	5 min	30 min before Paclitaxel (d1)
1	Dimetinden	4 mg	NaCl 0.9% 50 ml	i.v.	5 min	30 min before Paclitaxel (d1)
1	Cimetidine	300 mg	NaCl 0.9% 50 ml	i.v.	5 min	30 min before Paclitaxel (d1)

Antineoplastic therapy: Paclitaxel 80 mg/m²

CTX

Access: peripheral venous

weekly therapy

Day	Substance	Dosage	Solution	Appl.	Inf. time	Procedure
1	Paclitaxel	80 mg/m ² BSA	NaCl 0.9% 250 ml	i.v.	60 min	Sequence

Substance links

Links to substances are found [here](#).

Concomitant therapy supplements

Dexamethasone for antiemesis is covered by dexamethasone of allergy prophylaxis.

References

- Sparano JA, Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008 Apr 17;358(16):1663-71. doi: 10.1056/NEJMoa0707056. PMID: 18420499. [\[PMID\]](#)
- De Laurentiis M, Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008 Jan 01;26(1):44-53. doi: 10.1200/JCO.2007.11.3787. PMID: 18165639. [\[PMID\]](#)
- Budd GT, SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 2015 Jan 01;33(1):58-64. doi: 10.1200/JCO.2014.56.3296. PMID: 25422488. [\[PMID\]](#)
- Shulman LN, Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol 2014 Aug 01;32(22):2311-7. doi: 10.1200/JCO.2013.53.7142. PMID: 24934787. [\[PMID\]](#)

Links

- One-hour paclitaxel infusions: review of safety and efficacy. [\[PMID\]](#)

Recommendations

- 08/2019: [European Society for Medical Oncology](#)
- 03/2023: [National Comprehensive Cancer Network](#)



The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti.

Valid since: 16.09.2023